A unique partnership between industry and academia has led to human clinical trials of a new drug for a rare class of blood diseases called myeloproliferative disorders, which are all driven by the same genetic mutation and can evolve into leukemia.
blood diseasesStem Cell Research Leads To Potential New Therapy For Rare Blood...ScienceDaily Thu, 04/10/2008 - 01:00
|
